P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In

 

News Categories

 

 

 

Glaxo Walks Away From Lung Cancer Vaccine

Trial data fail to identify subgroup that would benefit from treatment

GlaxoSmithKline has announced its decision to stop the MAGRIT trial, a phase III study of its MAGE-A3 cancer immunotherapeutic agent in patients with non–small-cell lung cancer (NSCLC), after establishing that it will not be possible to identify a subpopulation of gene-signature positive NSCLC patients that may benefit from the treatment.

MAGRIT was a double-blind, randomized, placebo-controlled phase III trial designed to assess the efficacy of a recMAGE-A3 + AS15 antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with stage IB, II, and IIIA completely resected NSCLC whose tumors expressed the MAGE-A3 gene. The patients were given up to 13 intramuscular injections of either the MAGE-A3 immunotherapeutic or placebo over 27 months.

Data from the study, announced on March 20, showed that it did not meet its first or second co-primary endpoints as it did not significantly extend disease-free survival (DFS) when compared with placebo in either the overall MAGE-A3–positive population (first co-primary endpoint) or in MAGE-A3–positive patients who did not receive chemotherapy (second co-primary endpoint).

GSK continued with the MAGRIT trial to investigate the third co-primary endpoint of DFS in a gene signature-positive subpopulation. This analysis was designed to identify a subset of MAGE-A3–positive patients that may benefit from the treatment. However, the pre-planned independent third-party analysis of a proportion of the data (to identify a gene signature classifier) has concluded that assessment of the third co-primary endpoint is not feasible because of an insufficient treatment effect.

The trial will be stopped, and GSK will gain access to the unblinded data to conduct a full assessment of the findings.

MAGE-A3 is a tumor-specific antigen expressed in a variety of cancers but not in normal cells. In NSCLC, it is expressed in approximately one-third of tumors in patients with stage IB–IIIA disease.

The MAGE-A3 cancer immunotherapeutic consists of recombinant MAGE-A3 protein and the immunostimulant AS15 (a combination of the QS-21 Stimulon adjuvant, monophosphoryl lipid A, and CpG7909, a TLR-9 agonist, in a liposomal formulation). The QS-21 Stimulon adjuvant was licensed from Antigenics Inc, a subsidiary of Angenus, Inc.

GSK is conducting another phase III clinical trial (DERMA) to determine whether a gene signature can identify a subpopulation of melanoma patients that would benefit from the same investigational MAGE-A3 cancer immunotherapeutic. This follows the read-out of the first co-primary endpoint (in September 2013) of DFS in the overall MAGE-A3–positive population, which was not met. According to GSK, the company is working on a mathematical model (the gene signature classifier) to allow the assessment of DFS in the gene signature population, the second co-primary endpoint in the DERMA trial. The outcome is expected in 2015.

Source: GlaxoSmithKline; April 2, 2014.

More stories